The list of new safety and effectiveness reviews has been updated and now includes safety reviews initiated between May 1 and 31. 2026. The next update is scheduled for June 2026.
The data presented in the Canada Vigilance Adverse Reaction Online Database has been updated and now includes information received by Health Canada up to March 31, 2026. The next update of data is scheduled for early April 2026.
Content: Announcement: Breast implant recall subscription; 2025 AR data; Safety brief: Vitamin B6 health products and peripheral neuropathy.
The list of new safety and effectiveness reviews has been updated and now includes safety reviews initiated between April 1 and 30, 2026. The next update is scheduled for July 2026.
Content: Safety brief: Diosmin or diosmin in combination with hesperidin; Lunsumio / Lunsumio SC: Authorization with conditions
The data presented in the Canada Vigilance Adverse Reaction Online Database has been updated and now includes information received by Health Canada up to January 31, 2026. The next update of data is scheduled for early June 2026.
The list of new safety and effectiveness reviews has been updated and now includes safety reviews initiated between March 1 and 31, 2026. The next update is scheduled for June 2026.
Safety brief: Falsely elevated digoxin levels; Product monograph update: Taro-Melphalan
Safety brief: Falsely elevated digoxin levels; Product monograph update: Taro-Melphalan
The data presented in the Canada Vigilance Adverse Reaction Online Database has been updated and now includes information received by Health Canada up to December 31, 2025. The next update of data is scheduled for early May, 2026.
